Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia

Oncotarget

Volumn 7, Issue 7, 2016, Pages 7586-7596

  Sander, Frida Ewald ^a   Rydström, Anna ^a   Bernson, Elin ^a   Kiffin, Roberta ^a   Riise, Rebecca ^a   Aurelius, Johan ^a,b   Anderson, Harald ^c   Brune, Mats ^b   Foà, Robin ^d   Hellstrand, Kristoffer ^a   Thorén, Fredrik B ^a   Martner, Anna ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; And immunity; Antigen specific t cells; Cytotoxic T cells; Immune response; Immunology and microbiology section; Immunotherapy

Indexed keywords

HISTAMINE; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; HISTAMINE AGONIST;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CENTRAL MEMORY CELL; CONTROLLED STUDY; EFFECTOR CELL; EFFECTOR MEMORY CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA FREE SURVIVAL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAIVE T CELL; OVERALL SURVIVAL; RELAPSE; REMISSION; SURVIVAL; T LYMPHOCYTE SUBPOPULATION; ADOLESCENT; AGE; CANCER STAGING; CELL CULTURE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; FLOW CYTOMETRY; FOLLOW UP; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HISTAMINE; HISTAMINE AGONISTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 84958779561     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7210     Document Type: Article

References (26)

1. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, Wheatley K, Hunter A and Russell N. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of clinical oncology. 2013; 31:1293-1301.
2. Martner A, Thoren FB, Aurelius J and Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood reviews. 2013; 27:209-216.
3. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001; 411:385-389.
4. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008; 112:4371-4383.
5. Montagna D, Maccario R, Locatelli F, Montini E, Pagani S, Bonetti F, Daudt L, Turin I, Lisini D, Garavaglia C, Dellabona P and Casorati G. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood. 2006; 108:3843-3850.
6. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H and Bullinger L. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood. 2006; 108:4109-4117.
7. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E and Bonnet D. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014; 28:1596-1605.
8. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:13824-13829.
9. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmuller G, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016; 30:484-91.
10. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006; 108:88-96.
11. Farber DL, Yudanin NA and Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014; 14:24-35.
12. Sallusto F, Geginat J and Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22:745-763.
13. Rosenberg SA and Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348:62-68.
14. Restifo NP and Gattinoni L. Lineage relationship of effector and memory T cells. Current opinion in immunology. 2013; 25:556-563.
15. Roychoudhuri R, Lefebvre F, Honda M, Pan L, Ji Y, KlebanoffCA, Nichols CN, Fourati S, Hegazy AN, Goulet JP, Gattinoni L, Nabel GJ, Gilliet M, Cameron M, Restifo NP, Sekaly RP, et al. Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. Vaccine. 2015; 33:914-923.
16. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? ASH Education Program Book. 2012; 2012:1-6.
17. Liao W, Lin JX and Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Current opinion in immunology. 2011; 23:598-604.
18. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D and Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002; 100:2132-2137.
19. Greiner J, Schneider V, Schmitt M, Gotz M, Dohner K, Wiesneth M, Dohner H and Hofmann S. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood. 2013; 122:1087-1088.
20. Ko HS, Fu SM, Winchester RJ, Yu DT and Kunkel HG. Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J Exp Med. 1979; 150:246-255.
21. Arruvito L, Payaslian F, Baz P, Podhorzer A, Billordo A, PandolfiJ, Semeniuk G, Arribalzaga E and Fainboim L. Identification and clinical relevance of naturally occurring human CD8+HLA-DR+ regulatory T cells. J Immunol. 2014; 193:4469-4476.
22. Imamichi H, Lempicki RA, Adelsberger JW, Hasley RB, Rosenberg A, Roby G, Rehm CA, Nelson A, Krishnan S, Pavlick M, Woods CJ, Baseler MW and Lane HC. The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. Eur J Immunol. 2012; 42:2608-2620.
23. Thoren FB, Romero AI, Brune M and Hellstrand K. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert Opin Biol Ther. 2009; 9:1217-1223.
24. Martner A, Rydstrom A, Riise RE, Aurelius J, Anderson H, Brune M, Foa R, Hellstrand K and Thoren FB. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology. 2015: DOI: 10.1080/2162402X.2162015.1041701.
25. Martner A, Rydstrom A, Riise RE, Aurelius J, Anderson H, Brune M, Foa R, Hellstrand K and Thoren FB. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance Oncotarget. 2015:doi: 10.18632/oncotarget.15559.
26. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115:453-474.